Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals announced that a Business Transfer Agreement for transfer of the Company's Consumer Care Business to Glenmark Consumer Care, a wholly owned subsidiary of the Company, has been executed on 15 September 2025. The transaction is expected to be completed on or before 31 December 2025 subject to completion of customary conditions.Powered by Capital Market - Live

Ichnos Glenmark Innovation (IGI), Glenmark's wholly owned subsidiary, has received an upfront payment of $700 million from AbbVie (NYSE: ABBV). The payment is in accordance with the agreed contractual terms and is being made towards an exclusive global licensing agreement for IGI's lead investigational asset, ISB 2001 across North America, Europe, Japan, and Greater China markets.Powered by Capital Market - Live

Glenmark Pharmaceuticals announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The Company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrollment and dosing in the country. In parallel, Glenmark has submitted a Clinical Trial Application (CTA) in Russia and is preparing to open additional clinical trial sites in Brazil and Mexico, further expanding the global footprint of this pivotal study. The randomized, multi-center, Phase 3 trial will assess the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with resectable Stage IIIA and IIIB (N2) NSCLC, while a parallel Phase 3 study of Envafolimab sponsored by 3D Medicines Inc., was initiated in December 2023 and is actively recruiting in China. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. Glenmark's Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven' Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc., and the company will begin distribution in September 2025. According to IQVIA' sales data for the 12-month period ending July 2025, the Halaven' Injection, 1 mg/2 mL (0.5 mg/mL) market achieved annual sales of approximately $66.3 million. Powered by Capital Market - Live

The product is the therapeutic equivalent of Halaven Injection (1 mg/2 mL), originally developed by Eisai, Inc. Glenmark's version has been deemed bioequivalent and therapeutically equivalent by the U.S. Food and Drug Administration (USFDA), paving the way for its entry into the oncology segment of the U.S. injectable market. According to IQVIA sales data for the 12-month period ending July 2025, Halaven Injection recorded annual sales of approximately $66.3 million in the United States. Commenting on the launch, Marc Kikuchi, president & business head, North America said, 'We are pleased to announce the launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need.' Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company's consolidated net profit jumped 49.9% to Rs 215.48 crore on 7.4% rise in revenue from operations to Rs 1505.62 crore in Q1 FY26 over Q1 FY25. The scrip rose 0.53% to Rs 1,938.40 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals has fixed 15 September 2025 as record date for payment of dividend for FY 2025. Powered by Capital Market - Live

Glenmark Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live

The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine for Injection, 50 mg/vial and 100 mg/vial, originally developed by Astellas Pharma US, Inc. The company will begin distribution in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the U.S. market for Mycamine for Injection generated annual sales of approximately $60.7 million. Micafungin is an echinocandin antifungal used primarily in the treatment of candidemia, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Marc Kikuchi, president & business head, North America said, 'We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need.' Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication listed in Glenmark's approved label. All brand names and trademarks are the property of their respective owners. Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications. IQVIA National Sales Perspectives: Retail & Non-Retail, June 2025. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The scrip declined 1.38% to Rs 1,947.10 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine'2 for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA ' 021506 and the company will begin distribution in September 2025. According to IQVIA' sales data for the 12-month period ending June 2025, the Mycamine' for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million*. Powered by Capital Market - Live

Net profit of Glenmark Pharmaceuticals declined 86.23% to Rs 46.87 crore in the quarter ended June 2025 as against Rs 340.27 crore during the previous quarter ended June 2024. Sales declined 5.09% to Rs 3059.33 crore in the quarter ended June 2025 as against Rs 3223.30 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales3059.333223.30 -5 OPM %18.9818.25 - PBDT548.73580.12 -5 PBT418.81462.33 -9 NP46.87340.27 -86 Powered by Capital Market - Live